1211. |
|
|
1212. |
|
|
1213. |
|
|
1214. |
|
|
1215. |
- Nilsson, Peter
(författare)
-
Cardiovascular risk in the metabolic syndrome: fact or fiction?
- 2007
-
Ingår i: Current Cardiology Reports. - 1534-3170. ; 9:6, s. 479-485
-
Tidskriftsartikel (refereegranskat)abstract
- In population-based studies, a cluster of cardiovascular risk factors comprising the metabolic syndrome (MetS) has been documented as predictive of cardiovascular disease events and type 2 diabetes. Currently, there are several proposed definitions of the MetS, although data support some advantages of using the 2005 National Cholesterol Education Program Adult Treatment Panel III definition, which is considered superior to most others, including the one from the 2005 International Diabetes Federation study. One controversial issue is that some of the conventional cardiovascular risk factors included in the MetS cluster appear to be equally predictive of cardiovascular outcomes as the syndrome itself (eg, the influence of smoking habits). Further observational and intervention studies are needed to explore this issue and target the core problem of the syndrome, which is proposed to be insulin resistance. Useful therapies for the metabolic syndrome include lifestyle modification and drugs that lower conventional cardiovascular risk factors, such as metformin, the "glitazones," and evidence-based drugs.
|
|
1216. |
|
|
1217. |
|
|
1218. |
|
|
1219. |
|
|
1220. |
- Nilsson, Peter, et al.
(författare)
-
Diabetes och tobak - dubbla hot mot hälsan
- 2002
-
Ingår i: Läkartidningen. - 0023-7205 .- 1652-7518. ; 99:20, s. 2-2285
-
Tidskriftsartikel (refereegranskat)abstract
- Smoking is a serious risk factor for cardiovascular disease, retinopathy, and nephropathy in patients with diabetes. Furthermore, epidemiological studies have shown that heavy smokers run an increased prospective risk of developing type 2 diabetes, probably due both to the fact that smoking is a marker for an unhealthy lifestyle and that smoking via nicotine may deteriorate glucose metabolism by negatively influencing insulin sensitivity. In Sweden, data from the National Diabetes Register (NDR) has shown that the prevalence of smoking in type 2 diabetes patients followed in primary health care is almost as high as in the non-diabetic population, at least in middle-aged subjects (about 20%). This alarming situation must be dealt with by using new and effective methods to promote anti-smoking. If support by group sessions can be organised for patients with type 2 diabetes who are smokers, in combination with pharmacological approaches (nicotine, bupropion) it is hoped that the rate of smoking cessation can substantially increase. Such projects are currently under-way within the primary health care in southern Sweden.
|
|